<u> </u>			ap/1647		
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))  Docket No. 1059.00051					
In Re Application Of:	Dexian Dou et al.	007 55	7/2840		
Serial No. 09/914,277	Filing Date RADEMA 03/25/02	Examiner	Group Art Unit 1647		
Title: ANTI-ANGIOGENIC KRINGLE PROTEIN AND ITS MUTANTS  RECEIVED					
			SEP 2 5 2002		
	Assistant Com	ddress to: nmissioner for Patents pton, D.C. 20231	TECH CENTER 1600/2900		
	37 C	FR 1.97(b)			
application; befo	the date of entry of the national ore the mailing of a first Office Ac filing of a request for continued e	tion on the merits, or before t	he mailing of a first Office		
CFR 1.97(b), pr Final Action un	Disclosure Statement submitted rovided that the Information Disclored 37 CFR 1.113, a Notice of sprosecution in the application, a	I herewith is being filed after closure Statement is filed bef f Allowance under 37 CFR	ore the mailing date of a 1.311, or an Action that		
☐ the staten	nent specified in 37 CFR 1.97(e);				
OR					
the fee set forth in 37 CFR 1.17(p).					
			ł.		

TRANSMITTAL OI	F INFORMATION DISCLO	SURE STATEMENT	Docket No.
Œ	30X	1059.00051	
In Re Application: D	Dexian Dou et al.  SEP 2	3 2002	
Serial No.	Filing Date	Examiner	Group Art Unit
09/914,277	03/25/02	ENW.	1647
ANTI-ANGIOGE	NIC KRINGLE PROTEIN AND I	TS MUTANTS	RECEIVED
			SEP 2 5 2002
			TECH CENTER 1600/290
	Payn	nent of Fee	·
	(Only complete if Applicant ele	ects to pay the fee set forth in 37 CFR 1.	.17(p))
as described belo Charge th Credit any Charge a Certificate of T	ow. A duplicate copy of this sheet the amount of y overpayment.  In additional fee required.  Fransmission by Facsimile*  The and authorization to charge deposition of the United States	Certificate of Mailing by	fee is being deposited the U.S. Postal Service C.F.R. 1.8 and is not something to the control of
Typed or Printed N	Jame of Person Signing Certificate	Typed or Printed Name of Person	on Mailing Certificate
	PLLC way	Dated: September 20, 2002	
cc:			



## MANUAL OF PATENT EXAMINING PROCEDURE

TRADEMARK				Sheet <u>1</u> of <u>3</u>			
Form PTO-1449				Docket Number (Optional) Application Number 1059.00051 09/914,277			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Dexian Dou, et al.				
(Use several sheets if necessary)			Filing Date 03/25/02		Group Art Unit 1647		
		U.S.	PATEN	T DOCUMENT	S		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,791,932	02/12/74	Schuurs e	et al.			01/27/72
	3,839,153	10/01/74	Schuurs e	et al.			12/10/71
	3,850,752	11/26/74	Schuurs et al.				10/29/71
	3,850,578	11/26/74	McConnell				02/19/74
	3,853,987	12/10/74	Dreyer				09/01/71
	3,867,517	02/18/75	Ling				12/21/71
	3,879,262	04/22/75	Schuurs e	et al.			05/01/73
	3,901,654	08/26/75	Gross				06/21/71
	3,935,074	01/27/76	Rubenste	in et al.			12/17/73
	3,984,533	10/05/76	Uzgiris				11/13/75
	3,996,345	12/07/76	Ullman et	al.			03/30/75
	4,034,074	07/05/77	Miles				09/19/74
	4,098,876	07/04/78	Piasio et	al.			10/26/76
	4,439,196	03/27/84	Higuchi				03/18/82
	4,447,224	05/08/84	DeCant,	Jr. et al.			09/20/82
	4,447,233	05/08/84	Mayfield				07/30/82
	4,475,196	10/02/84	La Zor				03/06/81
	4,486,194	12/04/84	Ferrara				06/08/83
	4,487,603	12/11/84	Harris				11/26/82
	4,666,828	05/19/87	Gusella				08/15/84
	4,683,202	07/28/87	Mullis				10/25/85

SEP 2 5 2002



SEP 2 5 2002

	ENT & THE	DEMARK	TECH CE	NITED 10	00/2000		
4,801	4,801,531 01		Frossard	VILITIO	00/2300	09/30/85	
4,866	4,866,042		Neuwelt			11/18/87	
4,879	4,879,219		Wands et al.			09/19/80	
4,925	4,925,678		Ranney			04/01/87	
4,959	,217	09/25/90	Sanders et al.			05/22/86	
5,011	,771	04/30/91	Bellet et al.			09/24/87	
5,167	,616	12/01/92	Haak et al.			12/14/89	
5,169	,383	12/8/92	Gyory et al.			10/02/89	
5,192	,659	03/09/93	Simons			07/11/90	
5,225	,182	07/06/93	Sharma			10/31/91	
5,272	,057	12/21/93	Smulson et al.			10/14/88	
5,281	,521	01/25/94	Trojanowski et al.			07/20/92	
5,464	5,464,764		Capecchi et al.			02/04/93	}
5,487	,992	01/30/96	Capecchi et al.			06/28/93	
		FORE	GN PATENT DOCUME	NTS			
DOC	KET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO
0	THER DOC	UMENTS	(Including Author, Title, Da	te Pertin	ent Pages. E	tc.)	·
	Ausubel et al. ( MD 1989.	CURRENT P	ROTOCOLS IN MOLECULAR	BIOLOGY	, John Wiley	and Sons, E	Baltimore,
	de Munk GA, Caspers MP, Chang GT, Pouwels PH, Enger-Valk BE, Verheijen JH. BINDING OF TISSUE-TYPE PLASMINOGEN ACTIVATOR TO LYSINE, LYSINE ANALOGUES, AND FIBRIN FRAGEMENTS, Biochemistry 1989, 28:7318-7325.						
	Gilboa E, Eglitis, MA, Kantoff PW, Anderson WF. Transfer and Expression of Cloned Genes Using						
	Retroviral Vectors, BioTechniques 1986, Vol. 4, No. 6, pages 504-512.  Hanahan D, Folkman J. PATTERNS AND EMERGING MECHANISMS OF THE ANGIOGENIC SWITCH						
	DURING TUMORIGENESIS, Cell 1996, 85:353-364.  Harris AL. ARE ANGIOSTATIN AND ENDOSTATIN CURES FOR CANCER?, Lanet May 30, 1998,						
	351:1598-1599. Innis MA, Gelfand DH, Sninsky JJ, White, TJ. PCR PROTOCOLS: A GUIDE TO METHODS AND						
1 1 1	APPLICATIONS	, Academic F	Press, San Diego, CA 1990.				j
			F STRUCTURAL PROTEINS D re 1970, 227(259):608-685.	URING II	HE ASSEMBL	Y OF THE	HEAD OF
			S FOR PROTEIN PURIFICATION	N AND C	HARACTERIZ	ZATION, CH	SL Press
			ELECTED METHODS IN CELI	LULAR IN	IMUNOLOGY	, W.H. Free	man and
	. Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Cold Springs Harbor Laboratory, NY 1989 and 1992.						
			INICAL IMMUNOLOGY 81H EDI	ITION, Apj	oleton & Lang	e, Norwalk,	CT 1994.

## RECEIVED

SEP 2 5 2002

## TECH CENTER 1600/2900

	Testoni N, Madural C, Farabegoli P, Zaccaria A, Amabile M, Raspadori D, Pelliconi, E, Carboni, Tura, S. A NEW METHOD OF "IN-CELL REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION" FOR THE DURATION OF BCR/ABL TRANSCRIPT IN CHRONIC MEYLOID LEUKEMIA PATIENTS, Blood
	May 1996, Vol 87, No. 9:3822-3827.  Wu Z, O'Reilly MS, Folkman J, Shing Y. SUPPRESSION OF TUMOR GROWTH WITH RECOMBINANT MURINE ANGIOSTATIN, Biochemical and Biophysical Research Communications 1997, 236:651-654.
EXAMINER	DATE CONSIDERED
	Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through n conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92) DEPARTMENT OF COMMERCE Patent and Trademark Office; U.S.